NCT02907099View on ClinicalTrials.gov

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

October 6, 2023

Study Completion Date

October 6, 2023

Conditions
Metastatic Pancreatic AdenocarcinomaRecurrent Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v6 and v7
Interventions
DRUG

CXCR4 Antagonist BL-8040

Given SC

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02907099 - Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter